Clinical Prognostic Score to Predict Relapse in VL
Learn more about:
Related Access Program
University of California, San Francisco – Leishmaniasis, Cutaneous
University of California, San Francisco – Leishmaniasis, Mucocutaneous
Universidad Peruana Cayetano Heredia – Cutaneous Leishmaniasis
U.S. Army Medical Research and Materiel Command – Leishmaniasis, Cutaneous
University of California, San Francisco – Leishmaniasis
U.S. Army Medical Research and Materiel Command – Leishmaniasis
Related Clinical Trial
Clinical Prognostic Score to Predict Relapse in VL
Incidence of Relapse and Post-Kala-Azar Dermal Leishmaniasis in South Sudan
Evaluation of Less Invasive Procedures for Visceral Leishmaniasis Treatment Efficacy Monitoring Test of Cure
Evaluation to Assess the Usability of rK28 for the Diagnosis of Visceral Leishmaniasis in Kenya
Documentation of Patient Outcomes for SSG/Allopurinol Combination Treatment in Ethiopia
A Clinical Study to Develop a Controlled Human Infection Model Using Leishmania Major-infected Sand Flies
Safety, Tolerability and Pharmacokinetics (PK) Investigation of GSK3494245 in Healthy Participants
Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre
Defining Skin Immunity of a Bite of Key Insect Vectors in Humans
Clinical Investigation of Infections Due to Leishmanial Parasites
Safety, False-Positive Reactions and Sensitizing Properties of Leishmania Tropica Skin Test Antigen
Safety, Tolerability and Pharmacokinetics (PKs) Investigation of GSK3186899 in Healthy Subjects
Frequency of Parasite Infection in Hyraxes and Sandflies During Outbreak of Leishmania Tropica Epidemic in The West Bank
Single Oral Dose Escalation Study of DNDI-0690 in Healthy Male Subjects
Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers
Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers
Diagnosis and Treatment of Leishmanial Infections
Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite
Efficacy Trial of Ambisome Given Alone and Ambisome Given in Combination With Miltefosine for the Treatment of VL HIV Positive Ethiopian Patients.
Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India
Mechanisms Relating to the Distinct in Vitro Susceptibility of Human Macrophages to L. Viannia Infection
Th1/Th2 Polarization and Linkage to L. Viannia Infection Outcomes
LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine
Open-Label, Sequential Step, Safety and Efficacy Study to Determine the Optimal Single Dose of Ambisome for Patients With VL
Steady State Global Bioequivalence Study of Amphotericin B Liposome for Injection 50 mg/ Vial in Fed Condition
Miltefosine (Long Course) for Bolivian Mucosal Leishmaniasis
Fractional CO2 Laser With Topical Pentostam Treatment for Cutaneous Leishmaniasis.
Pharmacokinetics of Miltefosine in Children and Adults
Trial to Determine Efficacy of Fexinidazole in Visceral Leihmaniasis Patients in Sudan
Miltefosine/Paromomycin Phase III Trial for Treatment of Primary Visceral Leishmaniasis (VL) Patients in Eastern Africa
Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite
WR 279,396 Open Label Treatment Protocol in Tunisia
Miltefosine for Mucosal Leishmaniasis
Asymptomatic Leishmania Infection in HIV Patients
Accuracy of a Rapid Diagnostic Test for Cutaneous Leishmaniasis in Morocco
Phase 3 Study of Walter Reed (WR) 279,396 and Paromomycin Alone for the Treatment of Cutaneous Leishmaniasis in Panama
Oral Miltefosine for the Treatment of Pediatric Cutaneous Leishmaniasis in Colombia
Miltefosine for Brazilian Visceral Leishmaniasis
Cosmetic Outcome of Leishmaniasis Scar After WR279396 Application
Prospective Observational Study of Intralesional Treatment With Pentostam in Cutaneous Leishmaniasis Israeli Patients
Efficacy/Safety of Sodium Stibogluconate (SSG) Versus Paromomycin (PM) and SSG/PM Combination to Treat V Leishmaniasis
Intralesional Antimony for Bolivian Cutaneous Leishmaniasis
Thermotherapy + a Short Course of Miltefosine for the Treatment of Uncomplicated Cutaneous Leishmaniasis in the New World¨
Efficacy of Radio-frequency Induced Heat (RFH)Therapy in Treatment of Cutaneous Leishmaniasis in India
Safety and Immunogenicity of a Vaccine for Cutaneous Leishmaniasis Using Recombinant Human Interleukin-12 and Aluminum Hydroxide Gel as Adjuvants
Pharmacokinetics/Safety of Miltefosine Allometric Dose for the Treatment of Visceral Leishmaniasis in Children in Eastern Africa
LAMP Assay for the Diagnosis of Visceral Leishmaniasis
Imiquimod Plus Antimony Immunochemotherapy for Cutaneous Leishmaniasis
Topical Liposomal Amphotericin B Gel Treatment for Cutaneous Leishmaniasis
A Community Trial for Visceral Leishmaniasis (VL)
Fourth-generation Immucillin Derivative DI4G Associated Therapy in Cutaneous Leishmaniasis
Pilot Study Using a Heat Pack to Treat Cutaneous Leishmaniasis
Expand Access/Assess Safety and Efficacy of Paromomycin IM Injection for the Treatment of Visceral Leishmaniasis
Mediterranean Visceral Leishmaniasis With Leishmania Infantum
Efficacy and Safety of Miltefosine or Thermotherapy for Cutaneous Leishmaniasis in Colombia.
An Effectiveness Study of Paromomycin IM Injection (PMIM) for the Treatment of Visceral Leishmaniasis (VL) in Bangladesh
Treatment of Leishmaniasis With Impavido® (Miltefosine): Higher-Weight Patient Registry
Allopurinol, Glucantime, or Allopurinol/Glucantime for Cutaneous Leishmaniasis in Brazil
Controlled Nitric Oxide Releasing Patch Versus Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis
Safety and Efficacy of Low-Dose Pentavalent Antimony for Treatment of Cutaneous Leishmaniasis
Amphotericin B to Treat Visceral Leishmaniasis in Brazilian Children
Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis
Reduced Doses of Antimony Plus Ranulocyte Monocyte Colony Stimulating Factor (GM-CSF) for Cutaneous Leishmaniasis
Topical 3% Amphotericin B Cream for the Treatment of Cutaneous Leishmaniasis in Colombia
Surveillance for Leishmaniasis Skin Lesions in Mali
Oral Miltefosine Plus Topical Imiquimod to Treat Cutaneous Leishmaniasis
Expression of Mif Alleles in Individuals With Leishmaniasis
Miltefosine and GM-CSF in Cutaneous Leishmaniasis
Immunogenetics of Visceral Leishmaniasis
WR 279,396 for the Treatment of Cutaneous Leishmaniasis
A Study to Assess Immune Response Status in Patients Before and After Treatment for Visceral Leishmaniasis
Efficacy and Safety Study of Drugs for Treatment of Visceral Leishmaniasis in Brazil
Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis
Phase 3 Study to Evaluate WR 279,396 vs. Paromomycin Alone to Treat Cutaneous Leishmaniasis (in Tunisia)
Clinical Trial of Miltefosine to Treat Mucosal Leishmaniasis
Amphotericin B Treatment in Visceral Leishmaniasis
The Association of Miltefosine and Pentoxifylline to Treat Mucosal Leishmaniasis: A Clinical Trial in Brazil
Miltefosine to Treat Mucocutaneous Leishmaniasis
A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis
High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus
Treatment of Cutaneous Leishmaniasis With a Combination of Miltefosine and Antimony
Safety and Efficacy of Azithromycin to Treat Cutaneous Leishmaniasis
Improved Case Detection and Vector Control for Visceral Leishmaniasis
Local Heat Therapy Versus Sodium Stibogluconate for the Treatment of Cutaneous Leishmaniasis
Short Course of Miltefosine and Liposomal Amphotericin B for Kala-azar
SCH708980 With and Without AmBisome for Visceral Leishmaniasis
Miltefosine to Treat Cutaneous Leishmaniasis in Bolivia
Single Infusion of Liposomal Amphotericin B in Indian Visceral Leishmaniasis
Combination Chemotherapy for the Treatment of Indian Kala-Azar
Efficacy, Acceptability and Cost-effectiveness of Long Lasting Insecticide Nets (LLIN) in the Prevention of Kala Azar
Immune Response of Visceral Leishmaniasis PatientsTreated With Antimonial Plus N-Acetylcysteine
Comparison of Standard and Alternative Antimonial Dosage in Patients With American Cutaneous Leishmaniasis
An Open Lable Randomised Study to Assess the Safety and Efficacy of Short Course Paromomycin in Visceral Leishmaniasis
Antimony Plus Pentoxifylline in Cutaneous Leishmaniasis
Topical Treatment of Cutaneous Leishmaniasis With WR 279,396: A Phase 2 Study in the Old World
Add-on Study of Pentoxifylline in Cutaneous Leishmaniasis
Sodium Stibogluconate Treatment of Leishmaniasis
A Pilot Study for Capacity Building for a Multi-centre, Randomized Trial for Treatment of Kala Azar in Bangladesh
Use of Sodium Stibogluconate as a Treatment for Leishmaniasis
Visceral Leishmaniasis and Malnutrition in Amhara Regional State, Ethiopia
A Phase II Study To Assess Safety and Efficacy Of Short-Course Regimens Of Amphotericin B Emulsion In Kala-Azar
Single Dose Liposomal Amphotericin B for Visceral Leishmaniasis
Topical Treatment of Recalcitrant Ulcerative Old World Leishmaniasis With WR 279,396